Bariatric Surgery Candidate Clinical Trial
Official title:
A Technology-based Intervention to Reduce Alcohol Use After Bariatric Surgery
Despite bariatric surgery being the most effective weight loss intervention for patients who are severely obese, as many as 1 in 5 patients will develop an alcohol use disorder after their surgery. Changes in metabolism, hormone levels, and behavior as a result of bariatric surgery alter the rewarding effects of alcohol while concurrently changing its absorption rate, putting patients at significantly elevated risk of hazardous drinking. Simply providing education to this vulnerable patient population about post-surgical risks has not been sufficient to reduce alcohol use, yet comprehensive in-person interventions are met with significant challenges, including hours-long distances between patients and their bariatric surgery programs. Thus, the long-term goal is to increase access to an empirically-supported intervention for reducing alcohol use among patients who undergo bariatric surgery by leveraging technology. This intervention, rooted in motivational interviewing and the transtheoretical model, is a two-session computerized brief intervention CBI, supplemented by six months of tailored text messaging based on participants CBI results and subsequent fluctuations in their readiness to change. The purpose of the proposed study is to optimize this technology-based intervention for patients who undergo bariatric surgery and to examine feasibility and acceptability of the intervention. In the first phase, patient interviews will be utilized to identify preferences for intervention content and treatment delivery. Ten patients will then participate in an open trial of the intervention, which will be subsequently revised based on feedback from these patients. In Phase 2, patients will be recruited between 3 and 6 months following bariatric surgery and randomized to the intervention or treatment as usual control group. All patients will complete baseline questionnaires and at 1, 3, 6, and 9 month post-assessments. The investigators expect that this intervention will be both feasible and acceptable to patients. Results will be used as preliminary data to inform a large, fully-powered clinical trial to test the larger efficacy of this intervention.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Underwent a bariatric surgery procedure between 3 and 6 months prior to the recruitment date - Has not consumed alcohol since undergoing bariatric surgery Exclusion Criteria: - History of an alcohol use disorder - Never consumed alcohol prior to surgery - Does not have a cellular phone that can receive and send text messages - No access to internet to complete the computerized brief intervention (CBI) |
Country | Name | City | State |
---|---|---|---|
United States | Henry Ford Health | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Henry Ford Health System | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Drinking Motives | The Drinking Motives Questionnaire-Revised (DMQ-R) assesses respondents' reasons for drinking across four categories: conformity, coping, enhancement, and social. Each subscale has scores that range from 5-25, with higher scores indicating greater motivation to use alcohol. | 6 months post-baseline | |
Other | Depression | Patient Health Questionnaire depression scale (PHQ-8) will measure depression scores. Scores range from 0-24 with higher scores indicating greater levels of depression. | 6 months post-baseline | |
Other | Anxiety | Measured by the Generalized Anxiety Disorder-7 (GAD-7). Scores range from 0-21 with higher scores indicating greater levels of anxiety. | 6 months post-baseline | |
Other | Food addiction | Yale Food Addiction Scale 2.0 (YFAS 2.0) will assess for symptoms of food addiction (similar to substance use disorder criteria in the DSM-V). Responses result in a symptom count that can range from 0-11 symptoms, with a higher number indicating more symptoms of food addiction. The scale can also indicate whether the symptoms are clinically significant (i.e., yes or no), and the scale can also give a determination of whether someone meets criteria for food addiction (yes or no), and if so, will determine if the addiction is considered mild, moderate, or severe. | Baseline and 1, 3, and 9 month follow ups | |
Primary | Time to alcohol use | The number of days that elapsed from surgery until the first alcoholic drink | 6 months post-baseline | |
Primary | Number of drinking days | The number of drinking days/days abstinent | 6 months post-baseline | |
Primary | Drinks per day | Average drinks per sitting | 6 months post-baseline | |
Secondary | Risky alcohol use | Definition of at-risk drinking from the National Institute of on Alcohol Abuse and Alcoholism (i.e., more than 3 drinks in a day for women or 4 for men or more than 7 drinks in a week for women or 14 drinks for men) | 6 months post-baseline | |
Secondary | Hazardous alcohol use | Scores on Alcohol Use Disorder Identification Test-Concise. Scores range from 0-12, with higher scores indicating greater potential for hazardous use. Scores of 3+ for women or 4+ for men indicate hazardous use. | 6 months post-baseline | |
Secondary | Importance of and confidence in the ability to abstain from alcohol | Measured on 0-10 scales; with higher scores indicating greater importance and confidence | 6 months post-baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Active, not recruiting |
NCT04583683 -
Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities
|
N/A | |
Completed |
NCT04099654 -
The Effect of Core Stabilization Exercise Program in Obese Subjects Awaiting Bariatric Surgery
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT03638843 -
Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2
|
N/A | |
Withdrawn |
NCT05845359 -
Intraoperative Methadone for Postoperative Pain Control
|
Phase 4 | |
Not yet recruiting |
NCT04343040 -
Perioperative Evaluation of Glucose Profile Using Continuous Glucose Monitoring System in Glucose Intolerant Patients
|
N/A | |
Withdrawn |
NCT03095404 -
Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery
|
Early Phase 1 | |
Recruiting |
NCT03100292 -
Korean OBEsity Surgical Treatment Study
|
N/A | |
Active, not recruiting |
NCT04357119 -
Common Limb Length in One-anastomosis Gastric Bypass
|
N/A | |
Completed |
NCT03210207 -
Gastric Plication in Mexican Patients
|
N/A | |
Completed |
NCT04883268 -
Focusing on Body Functionality After Bariatric Surgery
|
N/A | |
Completed |
NCT02300168 -
Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery
|
N/A | |
Unknown status |
NCT01264120 -
The Impact of a Bariatric Rehabilitation Service on Patient Outcomes
|
N/A | |
Recruiting |
NCT03972319 -
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
|
Early Phase 1 | |
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|
||
Completed |
NCT04219852 -
Contraception and Bariatric Surgery: Evaluation of Contraception and Contraceptive Knowledge of Women Undergoing Bariatric Surgery at the University Hospital of Reims
|
||
Recruiting |
NCT05570474 -
Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery
|
N/A |